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The outgrowth of metastatic cells to bone depends on the interaction between multiple intrinsic and host
factors. In this issue of Cancer Cell, Sethi and colleagues report Notch signaling in bone cells as responsible
for promoting this outgrowth and provide evidence for a beneficial treatment effect of NOTCH inhibitors.Metastasis, the last and most devastating
stage of tumor progression, remains the
cause of 90% death in cancer patients.
The development of metastases requires
a series of sequential rate-limiting steps
through which malignant tumor cells
from the primary site invade into blood
and lymphatic vasculature, survive in the
circulation, lodge at distant organs, and
outgrow. The revised ‘‘seed and soil’’
theory, originally proposed by Steven
Paget a century ago, hypothesizes that
the outcome of metastasis depends on
crosstalk between predetermined cancer
cells (the ‘‘seeds’’) and specific organ
microenvironments (the ‘‘soil’’), which
release homeostatic factors (Fidler and
Poste, 2008). In the soil organ, the seed
cancer cells can enter either latent phase
or outgrowth phase.
The skeletal system is recognized as the
habitat of the hematopoietic stem cell as
well as the most common metastatic site
for breast cancer. Recently, a positive
feedback loop causing a ‘‘vicious cycle’’
has been identified, in which the out-
growth phase of the bone metastases is
determined by a bidirectional interaction
between the cancer cells and the bone
microenvironment. This crosstalk involves
growth factors and cytokines derived from
both host and cancer cells (Figure 1) (Kang
et al., 2003; Zhang et al., 2009).Seventy percent of breast cancer
patients are affected by bone metastasis,
manifested by skeletal-related events
such as severe bone pain and patholog-
ical fractures (Mundy, 2002). There is
much evidence that metastatic cancer
cells usurp the normal process of bone re-
modeling through stimulation of both
osteoclasts that resorb bone and osteo-
blasts that deposit bone, and the net
outcome of lesions depends on the
relative contribution of each cell type. In
the outgrowth (or osteolytic) phase,
multiple growth factors, including trans-
forming growth factor b (TGFb) and
insulin-like growth factor 1 (IGF1), are
released from the degraded bone matrix.
TGFb and IGF1 both enhance the growth
of cancer cells and stimulate them to
produce several cytokines, including
parathyroid hormone-related protein
(PTHrP), connective tissue growth factor
(CTGF), and interleukin 11 (IL11). PTHrP
and IL11 regulate the expression of osteo-
clastogenic factors receptor activator of
nuclear factor-kB ligand (RANKL) and os-
teoprotegerin (OPG) in osteoblasts,
whereas CTGF mediates both angiogen-
esis and invasion (Massague, 2008).
Additional cells, such as bone borrow-
derived stromal, endothelial, and hemato-
poietic cells, have all been shown to
contribute to the development of themac-rometastases and the production of
prometastatic factors (Joyce and Pollard,
2009). On the other hand, the processes
by which metastatic cancer cells directly
communicate with various types of cells
in the bone and bone marrow remains
an enigma in the field of bone metastasis.
Undoubtedly, fully answering such ques-
tions will provide the insight necessary
for the development of effective therapies
against bone metastasis.
Sethi et al. (2011) now provide both
experimental and preclinical evidence
that the Notch ligand Jagged1 plays
a critical role in the promotion of bone
metastatic outgrowth of breast cancer.
Using a bioinformatic approach that
correlates the gene expression pattern
of Notch signaling pathway components
(ligands, receptors, and downstream
targets) to bone metastasis, the authors
indentified a unique upregulation of
Jagged1, which was highly correlated
with human breast cancer metastases
to bone. To investigate the functional
role of Jagged1 in the development of
bone metastasis, the authors applied
two different types of Jagged1-express-
ing human breast cancer cell lines in
a xenograft mouse model. In the strongly
bone tropic cell lines with high levels of
Jagged1 expression, stable knockdown
of Jagged1 resulted in a reduction ofFebruary 15, 2011 ª2011 Elsevier Inc. 159
Figure 1. TheRole of Jagged1 in the ‘‘ViciousCycle’’ of Breast Cancer OsteolyticMetastases
The upper panel schematically describes the steps required for tumor progression from cancer initiation to
osteolytic metastases. After cancer initiation, the cells invade the blood vessel, home in the bone marrow,
andproceedwith the last phase,which is the osteolytic outgrowth. The lower panel showsanewviewof the
‘‘vicious cycle,’’ which is the focus of the article by Sethi et al (2011). Here, the breast cancer cells
expressing Jagged1 directly interact with osteoblasts and preosteoclasts, resulting in the release of active
IL6 and TGFb, respectively, promoting the tumor outgrowth. This positive feedback/crosstalk between the
breast cancer cells (the ‘‘seed’’) and thebonecells (the ‘‘soil’’) is crucial for thedevelopmentof breast cancer
bone macrometastases. The inhibitors of Notch signaling, IL6, and TGFbeta, which have been extensively
used in this study, are demonstrated in this figure, as they might be beneficial clinically in the future.
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Previewstumor outgrowth of bone lesions, while in
the weakly bone tropic cell lines with low
expression of Jagged1, overexpression
of Jagged1 resulted in a significant
increase tumor outgrowth of bone
lesions. In both cases, there was no
change in cells’ proliferative and invasive
abilities, either in culture or as primary
tumors, suggesting that Jagged1 is
necessary and sufficient to promote os-
teolytic bone metastasis.160 Cancer Cell 19, February 15, 2011 ª2011TGFb is a central component of the
‘‘vicious cycle’’ in bone metastatic
outgrowth (Massague, 2008). Using
gene-set enrichment analysis, the authors
found that Jagged1 is one of ten core
genes that respond to TGFb, among
them IL11 and CTGF, which have been
previously identified as targets of TGFb
in metastasis (Kang et al., 2003). Indeed,
Jagged1 mRNA and protein levels in
cultured breast cancer cells significantlyElsevier Inc.increased in the presence of excess
active TGFb, mimicking the in vivo patho-
logical environment of osteolytic bone
metastases. To confirm this finding, Sethi
et al. (2011) applied pharmacological
inhibitors and an inducible Smad4 knock-
down system to block TGFb signaling
in vitro and in vivo, verifying that Jagged1
is an essential target of the TGF-b
pathway. Notably, Jagged1 overexpres-
sion restored the ability of Smad4 knock-
down cells to generate osteolytic bone
metastasis. Those findings establish
Jagged1 as a critical component in this
‘‘vicious cycle.’’
The authors observed severe osteolytic
phenotype in the Jagged1-mediated
bone metastases, which is attributable
to elevated osteoclastic activity. The
classic view suggests that metastasized
cancer cells indirectly regulate osteo-
clastic activity via PTHrP-induced expres-
sion of osteoblast-derived RANKL and
OPG (Mundy, 2002). Augmented RANKL
to OPG ratio is responsible for one of the
major determinants of pathological osteo-
clastic activity and bone-destructive func-
tion. Using a co-culture system that
contains both tumor cells and preosteo-
clastic cells, Sethi et al. (2011) demon-
strated that Jagged1-expressing cells
directly interact with preosteoclast to
increase this activity by accelerating oste-
oclast differentiation and maturation. In
contrast, the authors show that RANKL
and OPG levels are not changed when
osteoblasts are co-cultured with tumor
cells. Furthermore, the pharmacological
inhibitor of Notch signaling suppresses
Jagged1-mediated Notch activity.
Although this finding still needs to be
confirmed in vivo, this new mechanism
advances our understanding of the
processes that underlie osteolytic bone
metastasis.
A persistent outgrowth of bone metas-
tases likely depends on many intrinsic
tumor cell-specific and bone/bone
marrow-specific factors. To identify
factors in the bone microenvironment
that promote outgrowth of metastatic
breast cancer, the authors performed
a series of elegant experiments using
a co-culture system that contains both
tumor cells and osteoblasts, the major
secretory cell of the skeletal system.
They first found that cultured tumor cells
acquired a growth advantage via acti-
vating Notch pathway in osteoblasts.
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of the co-cultured osteoblasts and found
IL6, a proproliferative cytokine involved in
bone metastasis (Ara et al., 2009), among
the upregulated genes. Using a combina-
tion of strategies, the authors nicely
demonstrate that IL6 is a downstream
target of the Jagged1-Notch-Rbpj-Hey1
cascade, and is released fromosteoblasts
to promote tumor proliferation.
Notch signaling is a central pathway for
regulating cell-cell interaction during
embryonic development and is also
involved in the pathogenesis of skeletal
diseases (Tao et al., 2010). Hence, it is
not unexpected that pharmacological
inhibitors that block Notch pathway
signaling will have a beneficial effect in
both co-cultured Jagged1-expressing
tumor cells and bone cells, as well as in
the mouse model. However, a remaining
clinically relevant question is whether
these inhibitors can inhibit the outgrowth
of bone metastasis in patients. Another
important area that is critical for clinical
translation would be the effect of Notchinhibition in other components of the skel-
etal system (Engin et. al., 2008), as well as
elsewhere in the body.
In summary, the work presented by
Sethi et al. (2011) identified a novel ‘‘seed
and soil’’ crosstalk mediated by the
TGFb-Jagged1-Notch-IL6 signaling
network that promotes the outgrowth of
bone metastasis. The knowledge gained
in this study contributes to our under-
standing of the pathogenesis of bone
metastases and aids in finding therapy
against it. In addition, it opens doors for
many remaining unanswered questions.
Does Jagged1 activate Notch signaling
in other bone marrow-residing cells?
How does Notch pathway interplay with
other factors involved in bonemetastasis?
Will the use of Notch inhibitors together
with inhibitors of IL6 or/and TGFb be
synergistic in halting bone metastasis?REFERENCES
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JAK2 gain-of-function mutations have been shown to cause myeloproliferative neoplasms. In this issue of
Cancer Cell, Liu et al. (2011) demonstrate that these JAK2 mutants, but not wild-type JAK2, directly phos-
phorylate PRMT5 and inhibit its arginine methyltransferase activity, establishing a link between mutant
JAK2 and histone arginine methylation.Janus kinase 2 (JAK2) is a ubiquitously ex-
pressed intracellular tyrosine kinase that
associates with the cytoplasmic domains
of hematopoietic cytokine receptors and
becomes activated upon these receptors
binding to their cognate ligands. Acti-
vatingmutations in JAK2 have been found
in the majority of patients with myelo-
proliferative neoplasms (MPN), which
represent clonal hematopoietic stem
cell diseases characterized by increasedproliferation of the erythroid, megakar-
yocytic, or myeloid lineages. The vast
majority of patients with MPN (about
80%) carry mutations in JAK2 codon
617 that exchanges a valinewith a phenyl-
alanine (JAK2-V617F) (Skoda, 2007).
This mutated JAK2-V617F is an activated
tyrosine kinase that renders hemato-
poietic cells hypersensitive for signals
from upstream cytokine receptors (Epo,
Tpo, and G-CSF) and phosphorylates(STAT3 and STAT5), as well as other
downstream signaling proteins. In
a minority of patients (less than 3% of
MPNs), JAK2 mutations have been found
in codon 539 (e.g., JAK2-K539L) or in
neighboring codons, leading to a variant
of MPN with selectively increased
numbers of erythroid cells. The mutant
JAK2 proteins were shown to activate
proliferation, inhibit apoptosis, and inter-
fere with genome stability. However, allFebruary 15, 2011 ª2011 Elsevier Inc. 161
